Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not listed Phase 1 Interventional

Dose Finding Study of L19TNF and Doxorubicin in Patients With STS

ClinicalTrials.gov ID: NCT04032964

Public ClinicalTrials.gov record NCT04032964. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Dose Finding Study of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF in Combination With Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study is aimed at evaluating the safety of L19TNF in combination with the most appropriate dose of doxorubicin.

Study identification

NCT ID
NCT04032964
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Philogen S.p.A.
Industry
Enrollment
2 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 5, 2019 (Actual)
Primary completion
Dec 2024 (Estimated)
Completion
Dec 2024 (Estimated)
Last update posted
Apr 8, 2024

2019 – 2024

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Sarcoma Oncology Research Center (SORC) Cancer Center of Southern California Santa Monica California 90403 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04032964, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 8, 2024 · Synced Nov 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04032964 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →